About
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon sustained release technology platform.
Explore Eyconis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.